Vitamin Placenta is BACK IN STOCK!
Israeli company uses placenta cells to treat critical COVID-19 patients

Israeli company uses placenta cells to treat critical COVID-19 patients

The company dosed three patients in two different hospitals in Israel under a compassionate use program for the treatment of COVID-19.

MARCH 30, 2020

Biologists work in a laboratory at Pluristem Therapeutics Inc. in Haifa (photo credit: BAZ RATNER/REUTERS)

 

Pluristem Therapeutics, a Haifa-based regenerative-medicine company, has treated its first three coronavirus patients in Israel with its placenta-based cell-therapy product.

“In this time of emergency, we are honored to be taking part in the global effort to support patients and healthcare systems,” Pluristem president and CEO Yaky Yanay said.

The company dosed three patients in two different hospitals in Israel under a compassionate-use program for the treatment of COVID-19. It was approved by the Health Ministry. 
Pluristem expects to enroll additional Israeli patients in the coming days. The company will share updates on clinical outcomes once significant data has been gathered, it said in a press release.
All the patients who have received the therapy are high risk. They are older, have preexisting medical conditions and have been intubated with a ventilator.
“Pluristem is closely following the medical condition of these patients in conjunction with the hospitals’ medical professionals delivering the care,” the press release said.
Pluristem said its PLX cells are “allogeneic mesenchymal-like cells that have immunomodulatory properties,” meaning they induce the immune system’s natural regulatory T cells and M2 macrophages. The result could be the reversal of dangerous overactivation of the immune system. This would likely reduce the fatal symptoms of pneumonia and pneumonitis (general inflammation of lung tissue).
Previous preclinical findings regarding PLX cells revealed significant therapeutic effects in animal studies of pulmonary hypertension, lung fibrosis, acute kidney injury and gastrointestinal injury.
The company is in discussions with regulators in the United States and Europe to “define our clinical strategy for COVID-19,” Yanay said.
“Pluristems’s advanced manufacturing capabilities enable us to serve potential needs of treating large numbers of patients under compassionate use and clinical studies across numerous countries and hospitals in accordance with our expansion program and regulatory approvals,” he said. “We are facing a very different global condition right now, and the entire Pluristem team is committed to be an important part of the solution.”
//

48 Comment

  • A fascinating discussion is worth comment.
    There’s no doubt that that you need to publish more
    on this subject, it might not be a taboo subject but typically
    folks don’t discuss these topics. To the next!
    Best wishes!!카지노

    Felicia
  • This is very interesting, You’re a very skilled blogger.

    I’ve joined your feed and look forward to seeking more of your excellent
    post. Also, I have shared your website in my social networks!카지노

    Dyan
  • Hey! Would you mind if I share your blog with my facebook group?
    There’s a lot of folks that I think would really appreciate your content.
    Please let me know. Thank you카지노

    Aja
  • Nice post. I was checking constantly this blog and I am impressed!
    Very helpful information specially the last part :) I care for
    such info much. I was seeking this particular information for
    a very long time. Thank you and best of luck.카지노

    Nelle
  • These are in fact fantastic ideas in regarding blogging.
    You have touched some pleasant things here. Any way keep up wrinting.카지노

    Brendan

Write a comment

Please note, comments must be approved before they are published

Comment are moderated